Alzheimer's Trials Fail; Blood Test Predicts Tau; Neuroscience Moves to Bluesky

(MedPage Today) -- Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ phase III trial, Cassava Sciences reported. The company stopped a second phase III study of the controversial...